Charles Schwab Investment Management Inc. Sells 15,599 Shares of LivaNova PLC (NASDAQ:LIVN)

Charles Schwab Investment Management Inc. decreased its holdings in LivaNova PLC (NASDAQ:LIVN) by 2.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 606,360 shares of the company’s stock after selling 15,599 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in LivaNova were worth $28,081,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Central Pacific Bank Trust Division raised its stake in LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after buying an additional 720 shares during the period. Captrust Financial Advisors bought a new position in shares of LivaNova during the third quarter worth approximately $217,000. Sanctuary Advisors LLC bought a new position in shares of LivaNova during the third quarter worth approximately $219,000. Edgestream Partners L.P. bought a new position in shares of LivaNova during the third quarter worth approximately $244,000. Finally, GSA Capital Partners LLP bought a new position in shares of LivaNova during the third quarter worth approximately $292,000. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LIVN. Mizuho lowered their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. Stifel Nicolaus lowered their target price on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of LivaNova in a research report on Monday. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $61.17.

LivaNova Trading Up 5.5 %

Shares of NASDAQ:LIVN opened at $41.41 on Tuesday. The business’s 50 day simple moving average is $45.88 and its 200 day simple moving average is $49.01. The company has a market capitalization of $2.25 billion, a P/E ratio of 98.60 and a beta of 1.10. LivaNova PLC has a 1 year low of $36.85 and a 1 year high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.